Scott Weir, PharmD, PhD

Director, Institute for Advancing Medical Innovation, University of Kansas Medical Center, Kansas City, KS 2009-Present

Associate Director – Translational Research, University of Kansas Cancer Center, Kansas City, KS 2012-Present

Program Co-Leader, Drug Discovery, Delivery and Experimental Therapeutics Research Program, University of Kansas CancerCenter, Kansas City, KS2006-2013; 2015-2017, 2019-2020

Acting Chief Scientific Officer, CicloMed LLC, Kansas City, MO2017-Present

Director, Office of Therapeutics, Discovery and Development, University of Kansas Cancer Center,Kansas City, KS 2006-2008

Senior Director, Preclinical Technologies, Aptuit LLC, Kansas City, MO 2005-2006

Vice President, Early Development and Laboratory Services, Quintiles Inc., Kansas City, MO 2000-2005

Executive Director, Biopharmaceutical Sciences, Quintiles, Inc., Kansas City, MO 1999-2000

Director, Drug Metabolism and Pharmacokinetics Department Hoechst, Marion, Roussel Inc., KansasCity, MO 1998-1999

Director, Pharmacokinetics Department, Hoechst, Marion, Roussel Inc., Kansas City, MO 1996-1998

Director and Acting Vice President, Pharmacokinetics Department, Hoechst, Marion, Roussel Inc.,Kansas City, MO 1995-1996

Director and Acting Vice President, Global Pharmacokinetics Department, Marion Merrell Dow Inc.,Kansas City, MO 1994-1995

Department Head, US Clinical Pharmacokinetics Department, Marion Merrell Dow Inc., Kansas City, MO 1992-1994

Team Leader, Clinical Pharmacodynamics Section, Clinical Pharmacology Department, MarionLaboratories Inc. and Marion Merrell Dow Inc., Kansas City, MO 1988-1992

Pharmacokineticist II, Clinical Pharmacokinetics Section, Clinical Pharmacology Department, MarionLaboratories, Inc., Kansas City, MO 1986-1988

My academic role at KUMC is focused on product development-focused translational science. I direct the Institute for Advancing Medical Innovation (IAMI) at KUMC. IAMI translates peer review-funded basic research into medical innovations, and using an industry approach, executes product development-focused translational research to de-risk the technologies with the intent of partnering those with promise. To date, IAMI has invested over $8.3M in 48 projects, ten of which have resulted in royalty-bearing licenses including the marketed drug product Epaned™. IAMI’s therapeutic areas of focus are cancer and rare diseases. Drugs and diagnostics are the priority technology areas, while IAMI is opportunistic when it comes to investing in advancing medical devices. Multi-disciplinary, multi-organizational project teams are formed with IAMI leadership. Empowered project teams are guided to develop milestone-based product development-focused translational research project plans.

Functional genomic landscape of acute myeloid leukaemia.

Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership.

CCN5 Therapy for Triple Negative Breast Cancer

Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis

Drug Repurposing Screen for Taxane-Resistant Triple-Negative Breast Cancer

Institutional Clinical and Translational Science Award

Prevention of Triple Negative Breast Cancer by Natural Compounds

Reducing Cancer Epithelial-to-Mesenchymal Transition and Tumor Metastases by Targeting the MK2 Pathway

Targeting Kinesin Family Member 15 for the Treatment of Cancer